The Mayo Clinic has been a member of the Eastern Cooperative Oncology Group (ECOG) for 37 years. This application is submitted to request funding via the U10 mechanism to continue as a main institution member of the ECOG. Mayo Clinic faculty and affiliated institutions have participated in key scientific roles including clinical and translational studies. The Mayo Clinic is an NCI-designated Comprehensive Cancer Center that has been continuously funded since 1973. Historically, the major strengths of the Mayo Clinic Cancer Center (MCCC) have been in high quality clinical research, practice-defining clinical trials, multidisciplinary translational studies, and biostatistics. Between 1/1/04 and 12/3/08, 4,114 patients were accrued to ECOG studies by the main institution, CGOPs, and secondary CCOPs. 98 full-length manuscripts were published with Mayo or Mayo affiliate authors and 89 abstracts were presented versus 55 papers and 58 abstracts in the previous grant cycle. Major accomplishments include the following. Mayo principal investigator authorship occurred on two trials with new agents that lead to FDA-approved indications (rituximab in diffuse large B-cell lymphoma (E4494 Dr. TM Habermann) and thalidomide in multiple myeloma (E1A04 Dr. SV Rajkumar). The thrombotic risks of high-dose dexamethasone changed the practice in myeloma (E4A03 Dr SV Rajkumar). In leukemia, Dr. GW Dewald as Chair of the Cytogenetics Committee, reported that a complex karyotype confers a poor prognosis with increased risk of treatment failure in acute lymphocytic leukemia. In multiple myeloma, new biologic insights were reported in the clinical implications of t(11,14) and tumor suppressor pl6 methylation by Dr. R. Fonseca and colleagues.
The specific aims are 1.) to contribute to accrual to ECOG studies as a main institution, and through CGOP programs and secondary CCOP programs, 2.) to provide clinical scientific leadership and resources to the ECOG consistent with the ECOG mission of reducing malignancy-related morbidity and mortality, 3.) to provide basic and translational scientific leadership and resources for the advancement of knowledge of the biology of malignant diseases with particular emphasis on disease-oriented expertise and/or programs unique to the Mayo Clinic, and 4.) to provide an administrative role in ECOG to support the Group's mission and goals.

Public Health Relevance

Participation and contributions in this mechanism have lead to new therapeutic approaches that have changed the natural history of diffuse large B-cell lymphoma and multiple myeloma improving patient survival. Biologic observations are predicting outcomes and moving to new therapeutic approaches in patients with outcomes as predicted by their presenting biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA013650-39
Application #
8067899
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2016-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
39
Fiscal Year
2011
Total Cost
$211,859
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2017) Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat 165:545-553
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004

Showing the most recent 10 out of 159 publications